Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KBP-089 in Type II Diabetes
NCT03907202Phase 1Terminated
- Sponsor
- KeyBioscience AG
- Start
- Apr 2018
- Primary completion
- Dec 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KBP-089 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by KeyBioscience AG. Primary endpoints: Treatment Emergent Adverse Events, Vital sign - Blood Pressure and 3 more. Started Apr 2018; status: terminated.
02
Drugs
KBP-089
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03907202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907202.